目的 分析2019—2022年我国9个城市125家医院肝素类药物使用情况，分析其使用趋势，为医院肝素类药物的科学管理和临床合理用药提供参考。方法 随机抽取参与中国药学会医院处方分析课题组研究的涉及使用肝素类药物的处方信息，并计算肝素类药物的销售金额、销售数量、用药频度（DDDs）、限定日费用（DDC）、销售金额排序（B）与DDDs排序（A）的比值以及年平均增长率（AARG），对临床应用情况进行分析。结果 共抽取使用肝素类药物处方/医嘱数据3 758 309条，涉及9个城市125家医院。使用肝素类药物患者男性多于女性，比例为1.1左右。2019—2022年销售金额排名第1位的为依诺肝素钠，销售数量排名第1位的为肝素钠，DDDs排名第1位的为依诺肝素钠，历年来只有贝米肝素钠DDC大于100元，其余肝素类药物DDC均在10～40元。结论 依诺肝素钠的B/A等于1，此药物使用同步性较好。那屈肝素钙B/A小于1，说明此药物使用频率低而价格偏高。相反肝素钠B/A大于1，此药物使用频率高而价格偏低。

Objective To analyze the use of heparins in 125 hospitals in 9 cities in China from 2019 to 2022, analyze their usage trends, and provide reference for the scientific management and clinical rational use of heparins in hospitals. Methods Randomly select prescription information related to the use of heparins from the research group on prescription analysis of hospitals under the Chinese Pharmaceutical Association, and calculate the sales amount, sales quantity, DDDs, DDC, sales amount ranking (B) to DDDs ranking (A), and annual average growth rate (AARG) of heparins to analyze their clinical application. Results A total of 3 758 309 prescriptions/medical orders for the use of heparins were extracted, involving 125 hospitals in 9 cities. More men than women use heparins, with a proportion of about 1.1. Between 2019 and 2022, enoxaparin sodium ranked first in terms of sales amount, heparin sodium ranked first in terms of sales quantity, and enoxaparin sodium ranked first in terms of usage frequency. Over the years, only bemiheparin sodium has a DDC greater than 100 yuan, while other heparinshave a DDC between 10 and 40 yuan. Conclusion The B/A of enoxaparin sodium is equal to 1, indicating good synchronicity in drug use. The B/A ratio of nadroparin calcium is less than 1, indicating that the frequency of use of this drug is low and the price is on the high side. On the contrary, if heparin sodium B/A is greater than 1, the frequency of use of this drug is high and the price is low.

R972

吴阶平医学基金会临床科研专项项目（320.6750.2020-11-26）；天津市卫生健康委员会科研项目（TJWJ2023QN114）